Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) — Capital Reinvestment Ratio
Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has a Capital Reinvestment Ratio of 1.89x as of December 2023, meaning it reinvests 2% of its operating cash flow (CN¥37.03 Million) in capital expenditures (CN¥70.15 Million). See Shandong Keyuan Pharmaceutical Co. Ltd. (301281) balance sheet quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Shandong Keyuan Pharmaceutical Co. Ltd. A Capital Reinvestment Ratio (2021–2023)
This chart tracks Shandong Keyuan Pharmaceutical Co. Ltd. A's Capital Reinvestment Ratio across 3 annual periods. Check total reinvestment intensity of Shandong Keyuan Pharmaceutical Co. Ltd. to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2023)
Year-by-year Capital Reinvestment Ratio for Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2023. For live market cap and broader valuation context, see market cap of Shandong Keyuan Pharmaceutical Co. Ltd. .
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.89x | CN¥37.03 Million | CN¥70.15 Million | ▲ +605.5% |
| 2022 | 0.27x | CN¥115.86 Million | CN¥31.11 Million | ▼ -30.8% |
| 2021 | 0.39x | CN¥52.02 Million | CN¥20.19 Million | — |